Department of Psychiatry, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, China.
Eur Arch Psychiatry Clin Neurosci. 2023 Jun;273(4):901-909. doi: 10.1007/s00406-022-01453-1. Epub 2022 Jul 6.
Despite growing concern about reproductive safety of antipsychotics, there is a paucity of research specifically assessing prenatal antipsychotic prescribing practices for psychotic disorders. This population-based cohort study identified women aged 15-50 years with diagnosis of psychotic disorders, who delivered their first and singleton child between 2003-2018 in Hong Kong, with an aim to examine temporal trends and predictors of prenatal antipsychotic use as well as antipsychotic utilization patterns before and during pregnancy. Data were retrieved from territory-wide medical-record database of public healthcare services. Of 804 women, 519 (65%) redeemed at least one prescription for antipsychotics during pregnancy. Older age at conception (25-34 years: OR 2.12 [95% CI 1.22-3.67]; 35-50 years: 2.52 [1.38-4.61]; 15-24 years as reference category) and antipsychotic treatment within 12 months pre-pregnancy (24.22 [16.23-36.16]) were significantly associated with prenatal antipsychotic use. Second-generation-antipsychotic (SGA) use during pregnancy increased over 16-year study period, while prenatal first-generation-antipsychotic (FGA) use showed declining trend. Overall antipsychotic and SGA use progressively decreased across pre-pregnancy and trimesters of pregnancy. Further analyses on antipsychotic use trajectories revealed that 87.4% (n = 459) of 529 women receiving antipsychotics in 12-month pre-pregnancy redeemed antipsychotic prescription during pregnancy, and 63.4% (n = 333) continued antipsychotic treatment throughout pregnancy. Only 7.5% of the cohort (n = 60) commenced antipsychotics in pregnancy. This is one of the few studies evaluating real-world prenatal antipsychotic utilization among women with psychotic disorders. Future research delineating risk conferred by illness-related factors and antipsychotic exposure on adverse maternal and fetal outcomes is warranted to facilitate treatment guideline development.
尽管人们越来越关注抗精神病药物的生殖安全性,但针对精神障碍患者的产前抗精神病药物处方实践,相关研究仍然很少。本项基于人群的队列研究纳入了 2003 年至 2018 年间在香港首次分娩且单胎的年龄在 15-50 岁之间的精神障碍女性患者,旨在评估产前抗精神病药物使用的时间趋势和预测因素,以及妊娠前和妊娠期间的抗精神病药物使用模式。研究数据来自于全港公共医疗服务的医疗记录数据库。在 804 名女性中,519 名(65%)在妊娠期间至少开具了一次抗精神病药物处方。受孕时年龄较大(25-34 岁:比值比 2.12[95%置信区间 1.22-3.67];35-50 岁:2.52[1.38-4.61];以 15-24 岁为参考类别)和妊娠前 12 个月内接受抗精神病药物治疗(24.22[16.23-36.16])与产前使用抗精神病药物显著相关。在整个研究期间,妊娠期间第二代抗精神病药物(SGA)的使用呈上升趋势,而第一代抗精神病药物(FGA)的使用呈下降趋势。总体而言,妊娠前和妊娠各期的抗精神病药物和 SGA 的使用逐渐减少。进一步的抗精神病药物使用轨迹分析显示,在妊娠前 12 个月接受抗精神病药物治疗的 529 名女性中,有 87.4%(n=459)在妊娠期间开具了抗精神病药物处方,有 63.4%(n=333)在整个妊娠期间继续接受抗精神病药物治疗。该队列中只有 7.5%(n=60)在妊娠期间开始使用抗精神病药物。这是为数不多的评估精神障碍女性患者真实世界产前抗精神病药物使用情况的研究之一。未来的研究需要明确疾病相关因素和抗精神病药物暴露对母婴不良结局的风险,以便为治疗指南的制定提供依据。